SageView Advisory Group’s Telix Pharmaceuticals TLX Stock Holding History

SageView Advisory Group’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$15	Buy	+2	New	+$19	﹤0.01%	2591

Other funds holding TLX

PIC

Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

SageView Advisory Group's TLX Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Telix Pharmaceuticals (TLX) in Q4 2025: 2 shares worth $15. The stake represents ﹤0.01% of the portfolio and ranks #2591 among its holdings.

40 funds tracked by Wall St. Rank hold TLX as of Q4 2025.

SageView Advisory Group held 2 shares of Telix Pharmaceuticals worth $15 as of Q4 2025.
Telix Pharmaceuticals was a new SageView Advisory Group position in Q4 2025.
Telix Pharmaceuticals made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2591 holding.
40 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.